<DOC>
	<DOCNO>NCT01303679</DOCNO>
	<brief_summary>In first-line metastatic breast cancer , bevacizumab-taxane progression toxicity , currently standard treatment . In patient express hormone receptor , show hormone therapy administer maintenance induction chemotherapy , could benefit regard progression-free survival . The investigator make hypothesis would interest discontinue treatment taxane 4 month , begin hormone therapy continue maintenance bevacizumab . Exemestane choose show potentially active patient progressed letrozole , anastrozole tamoxifen .</brief_summary>
	<brief_title>1st Line Treatment Bevacizumab-Taxane v Bevacizumab-Exemestane Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Age &gt; 18 an . Metastatic breast cancer locally advance RE+ , HER2 Patient receive paclitaxelbevacizumab first line chemotherapy Previous treatment exemestane ( adjuvant metastatic treatment ) . 1st line chemotherapy different thaan paclitaxelbevacizumab . Treatment paclitaxelbevacizumab &gt; 18 week . HER2 positifs et/ou récepteurs aux oestrogènes négatifs . Previous thrombosis event within 6 month inclusion . Previous significant surgery within 28 day treatment start Previuous coagulopathy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>First line metastatic breast cancer</keyword>
	<keyword>Positive estrogen receptor</keyword>
	<keyword>Negative HER2 receptor</keyword>
	<keyword>At least stable disease 4 month paclitaxel-bevcizumab induction chemotheray</keyword>
</DOC>